OncoScreen-AFP

Rapid Test for Alpha-Fetoprotein (AFP) – Liver Cancer (Hepatocellular Carcinoma) Screening

Overview:
OncoScreen-AFP is a rapid, point-of-care diagnostic test designed for the early detection and monitoring of hepatocellular carcinoma (HCC), the most common type of liver cancer. Utilizing lateral flow assay (LFA) technology, this test detects elevated levels of Alpha-Fetoprotein (AFP)—a widely recognized biomarker associated with liver tumors. OncoScreen-AFP delivers accurate results in under 15 minutes, making it ideal for use in clinical, rural, or high-risk screening environments.

Key Features:

AFP Biomarker Targeting: Measures total AFP levels in serum, plasma, or whole blood with clinical relevance for HCC detection.
Fast Turnaround: Provides clear results in less than 15 minutes at the point of care.
Clinically Actionable Thresholds: Calibrated to detect AFP concentrations commonly associated with liver tumors (>20 ng/mL).
User-Friendly Design: Requires minimal training; test can be performed in outpatient, field, or low-resource settings.
Scalable & Portable: Ideal for large-scale liver screening initiatives or integration into routine checkups for at-risk populations.

Clinical Applications:

Primary screening tool for liver cancer in high-risk groups (e.g., hepatitis B/C, cirrhosis)
Follow-up monitoring for patients previously diagnosed with HCC
Adjunct to imaging techniques (e.g., ultrasound, CT scan)
Outreach and mobile clinic testing in underserved regions

Benefits for Healthcare Providers:

Enhances early detection and improves patient prognosis
Provides rapid triage for high-risk liver disease patients
Reduces barriers to screening in rural and developing areas
Supports integration with surveillance programs for chronic liver conditions

Regulatory Status:
OncoScreen-AFP is CE-marked for clinical use in approved territories. Additional regulatory regulatory pathways for FDA approval and global distribution are in progress.